Casodex vs Placebo in Non-metastatic Early Prostate Cancer - SPCG6

Study identifier:D6876C00025

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Randomized, Double-Blind, Parallel-Group Trial Comparing Casodex 150mg Once Daily with Placebo in Patients with Non-metastatic Prostate Cancer.

Medical condition

Non-metastatic prostate cancer

Phase

Phase 3

Healthy volunteers

No

Study drug

Bicalutamide, Placebo

Sex

Male

Actual Enrollment

1218

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Oct 1995
Primary Completion Date: -
Study Completion Date: 01 Aug 2008

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

Scandinavian Prostate Cancer Group

Inclusion and exclusion criteria